Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.
Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.
Address: Top Floor, 111 Rathmines Road Lr, Dublin 6
Tel: 353 (01) 441 0024
GreenCross Publishing is owned by Graham Cooke.
HIQA has published a report on the significant economic burden of antimicrobial resistant infections on Irish public acute hospitals in 2019.
Antimicrobial resistance (AMR) is a global public health concern, driven largely by excessive and inappropriate use of antimicrobials in human and animal populations.
At the request of the Department of Health, HIQA undertook an analysis of the hospital costs associated with AMR. This work, part funded by the Health Research Board, supports Ireland’s First National Action Plan (iNAP) on Antimicrobial Resistance.
HIQA’s work included a literature review to inform an economic assessment of AMR. The subsequent analysis estimated the costs associated with eight selected antimicrobial-resistant bacteria of public health concern. HIQA found that over 4,700 of these resistant bacterial infections occurred across 50 public acute hospitals in Ireland in 2019. The study estimated that AMR associated with these bacteria cost the health service an additional €12 million in extra hospital bed days in 2019. HIQA also found that these resistant infections resulted in about 215 deaths and almost 5,000 DALYs, or years of full health lost.
Dr Máirín Ryan, HIQA’s Deputy CEO and Director of Health Technology Assessment, said: “Antimicrobial resistance also places a significant burden, both health and financial, on patients, carers and families. We estimated that AMR associated with these selected bacteria resulted in almost 5,000 DALYs in patients in 2019. To put this in context, this is similar to the burden reported in Ireland for certain cancers and rheumatoid arthritis.”
There are other important resistant micro-organisms and additional costs associated with managing AMR beyond extra bed days that were not examined in this study, due to the lack of available data. The estimated €12 million is therefore an underestimate of the total annual cost of managing all resistant infections in Ireland.
Dr Ryan continued: “There is a need for enhanced surveillance of AMR in Ireland. Enhanced surveillance and expanded public health capacity would enable earlier identification and management of AMR threats, as well as inform investment decisions by the Department of Health and the HSE.”
The IMO has commenced a ballot of NCHDs on industrial action up to and including strike...
The National Office of Clinical Audit (NOCA) has announced the publication of the National Paediatric Diabetes...
The ICGP is examining alternative pathways for entry into general practice training as part of efforts...
In December, the HSE released part of an external review into the case of 'Brandon', a...
The evidence on doctor burnout “should scare us and concern us”, the Director of the RCSI...
A review of public health governance structures and addressing “longstanding” IT infrastructure...
Leave a Reply
You must be logged in to post a comment.